Baillie Gifford & CO Clovis Oncology, Inc. Transaction History

Baillie Gifford & CO

  • $131 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 19, 2021
SELL
$4.06 - $5.8 $373 - $533
-92 Closed
0 $0
Q1 2021

May 06, 2021
SELL
$4.81 - $10.34 $240 - $517
-50 Reduced 35.21%
92 $1,000
Q4 2020

Feb 10, 2021
BUY
$4.13 - $6.41 $586 - $910
142 New
142 $1,000

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0
View Full List

About Clovis Oncology, Inc.

CLVS Quotes by TradingView
  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email